Suxibuzone

Summary

Suxibuzone (CHEMBL1414320) is an approved small-molecule prodrug (ATC M02AA22); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M02AA22
• Indications: 2 conditions
• Chemistry: 438.5 Da · C24H26N2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1414320
Name	Suxibuzone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5362
ChEBI	CHEBI:32173
ATC	M02AA22
Molecular formula	C24H26N2O6
Molecular weight	438.5
InChIKey	ONWXNHPOAGOMTG-UHFFFAOYSA-N

SMILES: CCCCC1(C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)COC(=O)CCC(=O)O

IUPAC name: 4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid

ChEBI definition: A pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses.

Pharmacological roles (ChEBI): prodrug, non-steroidal anti-inflammatory drug, antirheumatic drug, non-narcotic analgesic, peripheral nervous system drug.

Also known as: NSC-757866, Suxibuzona, Suxibuzone, SID11112710, SID56463081, SID144204166, SUXIBUZONE, SID144213095, SID144209550, SID124882557, SID170465972, suxibuzone

Patent coverage: 763 distinct patent families (2,988 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Beta-lactamase, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	5.25	Potency	5623	nM	CHEMBL_ACT_4659075
CYP2C19	5	Potency	10000	nM	CHEMBL_ACT_4016498

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).